Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Manning

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|May 28, 2011
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimenSteven P Treon, Christina Hanzis, Robert J Manning, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administrationSteven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|May 22, 2007
Fabrication of biomolecular nanostructures by scanning near-field photolithography of oligo(ethylene glycol)-terminated self-assembled monolayersMatthew Montague, Robert E Ducker, Karen S L Chong, et al.
Blood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|May 28, 2011
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimenSteven P Treon, Christina Hanzis, Robert J Manning, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administrationSteven P Treon, Christina K Tripsas, Bryan T Ciccarelli, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemiaLeukothea Ioakimidis, Christopher J Patterson, Zachary R Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemiaSteven P Treon, Christina Tripsas, Christina Hanzis, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|May 22, 2007
Fabrication of biomolecular nanostructures by scanning near-field photolithography of oligo(ethylene glycol)-terminated self-assembled monolayersMatthew Montague, Robert E Ducker, Karen S L Chong, et al.
Blood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.
British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Pageof 4